10 Best Growth Stocks to Buy and Hold for the Next Decade
On June 24, Dan Skelly, Morgan Stanley Wealth Management, appeared on a CNBC Television interview to discuss how investors should reposition for long-term compounding.
Adaptive Biotechnologies Corp (ADPT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 7,498,427 | $643,365,037 | 1.83% | |
| 2. | D E Shaw D. E. Shaw | 1,156,464.75 | $99,224,675 | +136% | 0.05% |
| 3. | Driehaus Capital Richard Driehaus | 631,925.75 | $54,219,229 | +45% | 0.31% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 631,155 | $54,153,099 | +27% | 0.02% |
| 5. | ARK Investment Management Catherine D. Wood | 522,576.5 | $44,837,058 | -1% | 0.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 2,500 | $50,000.00 | 2,500 | 2019-07-01 | Filing | |
| $20.00 | 1,000 | $20,000.00 | 1,000 | 2019-07-01 | Filing | |
| $20.00 | 300 | $6,000.00 | 300 | 2019-07-01 | Filing | |
| $20.00 | 400 | $8,000.00 | 400 | 2019-07-01 | Filing | |
| $20.00 | 500 | $10,000.00 | 500 | 2019-07-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.00 | 3,000 | $75,000.00 | 396,989 | 2026-08-10 | Filing | |
| $24.00 | 1,299 | $31,176.00 | 399,989 | 2026-07-30 | Filing | |
| $22.12 | 213,702 | $4,727,088.24 | 812,058 | 2026-07-21 | Filing | |
| $21.72 | 278,698 | $6,053,320.56 | 1,025,760 | 2026-07-21 | Filing | |
| $23.00 | 5,000 | $115,000.00 | 401,288 | 2026-07-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,784,789.75 | $324,734,962 | 0% | |
| 2. | 1,600,896.75 | $137,356,941 | 0% | |
| 3. | 1,477,841.5 | $126,798,802 | 0.02% | |
| 4. | 1,369,057.75 | $117,465,155 | 0.01% | |
| 5. | 1,066,911.25 | $91,540,985 | 0.3% |
News See All
10 Best Growth Stocks Under $20 to Buy
On May 29, Scott Wren, Senior Global Market Strategist at Wells Fargo Investment Institute, joined BNN Bloomberg to discuss the markets.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2026 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2026 Earnings Call Transcript May 5, 2026Adaptive Biotechnologies Corporation beats earnings expectations.
Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)?
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the best hot stocks under $20 to buy.
10 Hot Stocks Under $20 to Buy
On February 24, Luke Barrs, Goldman Sachs Asset Management chief business and client officer for fundamental equities, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends and ...
TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT)
On February 6, 2026, TD Cowen upgraded Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s price target to $21 from $20 while keeping a Buy rating, citing a Q4 beat and an improved outlook.
11 Most Volatile Stocks to Buy According to Hedge Funds
On February 17, 2026, Bloomberg reported that stocks fluctuated significantly as investors assessed the risks of artificial intelligence. The S&P 500 climbed 0.1%, while a software ETF sank 2.2%.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript February 5, 2026Adaptive Biotechnologies Corporation beats earnings expectations.
Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake
In separate regulatory filings last week, Adaptive Biotechnologies Corp.
Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why
Among others, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) said it expects its pharmaceutical services to generate $20 million in revenues, and anticipates EMR integrated testing volumes to exceed...